Loyal

Loyal on fru.dev

Loyal across fru.dev: timeline

  1. Loyal's large-dog lifespan drug LOY-003 earns FDA RXE (Emerging)
  2. Loyal: Series C $100M (Emerging)
  3. FDA accepts safety section for Loyal's LOY-002 (Emerging)
  4. Loyal completes enrollment of the STAY study at 1,300 dogs (Emerging)
  5. Loyal's STAY study enrolls 1,000 dogs (Emerging)
  6. FDA accepts efficacy case for Loyal's senior dog lifespan drug (Emerging)
  7. Loyal: Series B $45M (Emerging)
  8. Loyal doses the first dog in its LOY-002 pivotal lifespan study (Emerging)

Sources